Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 4/20 | 0.42 |
| ▸ | RORC | P51449 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13929229 | 0.87 | OPRM1 (0.50) | OPRM1RORC | |
| SCHEMBL13929443 | 0.84 | SIGMAR1 (0.54) | OPRM1RORC | |
| SCHEMBL13951542 | 0.83 | SIGMAR1 (0.53) | OPRM1RORC | |
| SCHEMBL13929318 | 0.82 | SIGMAR1 (0.56) | OPRM1RORC | |
| SCHEMBL13929312 | 0.82 | RORC (0.47) | OPRM1RORC | |
| SCHEMBL4220531 | 0.82 | SIGMAR1 (0.54) | OPRM1RORC | |
| SCHEMBL13930727 | 0.82 | OPRM1 (0.44) | OPRM1 | |
| SCHEMBL13929309 | 0.81 | SIGMAR1 (0.55) | OPRM1RORC | |
| SCHEMBL13929270 | 0.81 | SIGMAR1 (0.55) | OPRM1RORC | |
| SCHEMBL13929259 | 0.81 | RORC (0.44) | OPRM1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | ACKR3, CCR5, CCR7 | OPRM1 37/4885RORC 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.